State Street’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$162M Buy
5,043,590
+682,677
+16% +$25.3M 0.01% 1069
2025
Q4
$184M Buy
4,360,913
+161,239
+4% +$6.5M 0.01% 990
2025
Q3
$144M Buy
4,199,674
+1,029,974
+32% +$29.5M 0.01% 1138
2025
Q2
$85.7M Buy
3,169,700
+11,461
+0.4% +$332K ﹤0.01% 1392
2025
Q1
$93.6M Buy
3,158,239
+247,553
+9% +$9.44M ﹤0.01% 1299
2024
Q4
$115M Sell
2,910,686
-5,829
-0.2% -$221K ﹤0.01% 1257
2024
Q3
$99.3M Buy
2,916,515
+7,920
+0.3% +$223K ﹤0.01% 1326
2024
Q2
$63M Sell
2,908,595
-1,418,432
-33% -$29.8M ﹤0.01% 1542
2024
Q1
$95.9M Buy
4,327,027
+1,218,388
+39% +$29.7M ﹤0.01% 1336
2023
Q4
$85.5M Sell
3,108,639
-142,653
-4% -$3.44M ﹤0.01% 1402
2023
Q3
$72.6M Sell
3,251,292
-361,336
-10% -$9.29M ﹤0.01% 1397
2023
Q2
$92M Sell
3,612,628
-559,291
-13% -$13.6M ﹤0.01% 1278
2023
Q1
$93M Buy
4,171,919
+12,588
+0.3% +$304K 0.01% 1234
2022
Q4
$98.7M Sell
4,159,331
-1,064,565
-20% -$24.7M 0.01% 1169
2022
Q3
$86.7M Buy
5,223,896
+79,565
+2% +$1.79M 0.01% 1204
2022
Q2
$102M Buy
5,144,331
+1,198,461
+30% +$24.2M 0.01% 1130
2022
Q1
$109M Buy
3,945,870
+1,234,244
+46% +$35.3M 0.01% 1231
2021
Q4
$112M Buy
2,711,626
+275,487
+11% +$12.2M 0.01% 1214
2021
Q3
$113M Sell
2,436,139
-118,516
-5% -$5.17M 0.01% 1162
2021
Q2
$102M Buy
2,554,655
+389,722
+18% +$16.7M 0.01% 1268
2021
Q1
$116M Buy
2,164,933
+2,722
+0.1% +$157K 0.01% 1119
2020
Q4
$106M Sell
2,162,211
-21,991
-1% -$1.02M 0.01% 1104
2020
Q3
$71M Sell
2,184,202
-35,682
-2% -$1.13M ﹤0.01% 1191
2020
Q2
$57.5M Buy
2,219,884
+219,774
+11% +$5.48M ﹤0.01% 1360
2020
Q1
$48.6M Buy
2,000,110
+5,973
+0.3% +$150K ﹤0.01% 1262
2019
Q4
$55.7M Sell
1,994,137
-121,617
-6% -$3.15M ﹤0.01% 1445
2019
Q3
$50.8M Buy
2,115,754
+194,825
+10% +$5.18M ﹤0.01% 1426
2019
Q2
$54.8M Buy
1,920,929
+792,845
+70% +$19.8M ﹤0.01% 1430
2019
Q1
$28.2M Buy
1,128,084
+674,248
+149% +$12.9M ﹤0.01% 1820
2018
Q4
$5.71M Buy
453,836
+62,580
+16% +$740K ﹤0.01% 2657
2018
Q3
$3.74M Buy
391,256
+50,030
+15% +$552K ﹤0.01% 2993
2018
Q2
$3.19M Buy
341,226
+11,303
+3% +$79.5K ﹤0.01% 3066
2018
Q1
$1.83M Sell
329,923
-1,649
-0.5% -$10.2K ﹤0.01% 3204
2017
Q4
$2.16M Buy
331,572
+65,532
+25% +$487K ﹤0.01% 3156
2017
Q3
$2.33M Buy
266,040
+9,062
+4% +$73.7K ﹤0.01% 3133
2017
Q2
$2.14M Buy
256,978
+16,637
+7% +$136K ﹤0.01% 3106
2017
Q1
$2.21M Buy
240,341
+72,973
+44% +$597K ﹤0.01% 3048
2016
Q4
$1.3M Buy
167,368
+19,361
+13% +$145K ﹤0.01% 3229
2016
Q3
$1.13M Buy
148,007
+1,504
+1% +$8.5K ﹤0.01% 3157
2016
Q2
$741K Buy
146,503
+5,109
+4% +$27.4K ﹤0.01% 3332
2016
Q1
$763K Buy
141,394
+43,052
+44% +$255K ﹤0.01% 3276
2015
Q4
$709K Buy
98,342
+19,710
+25% +$133K ﹤0.01% 3282
2015
Q3
$370K Buy
78,632
+14,200
+22% +$135K ﹤0.01% 3383
2015
Q2
$716K Buy
64,432
+9,263
+17% +$91.2K ﹤0.01% 3309
2015
Q1
$401K Buy
55,169
+293
+0.5% +$2.4K ﹤0.01% 3400
2014
Q4
$530K Buy
54,876
+606
+1% +$4.73K ﹤0.01% 3381
2014
Q3
$529K Buy
54,270
+4,543
+9% +$59.6K ﹤0.01% 3371
2014
Q2
$852K Buy
49,727
+3,901
+9% +$56.2K ﹤0.01% 3275
2014
Q1
$785K Buy
45,826
+3,200
+8% +$51.1K ﹤0.01% 3293
2013
Q4
$619K Buy
+42,626
New +$555K ﹤0.01% 3327

Other funds holding VCYT

State Street's VCYT Position: Q1 2026 in Review

State Street increased its Veracyte (VCYT) stake by 16% in Q1 2026, buying an estimated $25.3M and bringing the position to 5,043,590 shares worth $162M. The position accounts for 0.01% of the portfolio, ranked #1069.

State Street first reported a position in VCYT in Q4 2013 and has held it in 50 quarters since. The position peaked at $184M in Q4 2025. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • State Street held 5,043,590 shares of Veracyte worth $162M as of Q1 2026.
  • State Street bought 682,677 Veracyte shares in Q1 2026, an estimated $25.3M.
  • Veracyte made up 0.01% of State Street's portfolio in Q1 2026, its #1069 holding.
  • State Street first reported a position in Veracyte in Q4 2013 and has held it in 50 quarters since.
  • State Street's Veracyte position peaked at $184M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.